Prognostic factors for nonrelapse mortality at primary treatment failure by multivariate proportional hazards analysis (n = 89)
| Prognostic factor . | n (%) . | Coefficient . | HR . | 95% CI . | P value . |
|---|---|---|---|---|---|
| No skin involvement or ≤ 50% | 23 (25.8) | — | 1.00 | — | |
| Skin involvement > 50% | 66 (74.2) | 1.6 | 4.99 | 1.46-16.99 | .01 |
| Platelet count ≥ 100 K/mm3 | 43 (49.4) | — | 1.00 | — | |
| Platelet count < 100 K/mm3 | 44 (51.6) | 0.82 | 2.27 | 1.12-4.61 | .02 |
| De novo or quiescent-type | 51 (57.3) | — | 1.00 | — | |
| Progressive-type onset | 38 (42.7) | 0.9 | 2.45 | 1.29-4.67 | .006 |
| KPS ≥ 50% | 51 (57.3) | — | 1.00 | — | |
| KPS < 50% | 38 (42.7) | 1.2 | 3.39 | 1.72-6.68 | < .001 |
| Prognostic factor . | n (%) . | Coefficient . | HR . | 95% CI . | P value . |
|---|---|---|---|---|---|
| No skin involvement or ≤ 50% | 23 (25.8) | — | 1.00 | — | |
| Skin involvement > 50% | 66 (74.2) | 1.6 | 4.99 | 1.46-16.99 | .01 |
| Platelet count ≥ 100 K/mm3 | 43 (49.4) | — | 1.00 | — | |
| Platelet count < 100 K/mm3 | 44 (51.6) | 0.82 | 2.27 | 1.12-4.61 | .02 |
| De novo or quiescent-type | 51 (57.3) | — | 1.00 | — | |
| Progressive-type onset | 38 (42.7) | 0.9 | 2.45 | 1.29-4.67 | .006 |
| KPS ≥ 50% | 51 (57.3) | — | 1.00 | — | |
| KPS < 50% | 38 (42.7) | 1.2 | 3.39 | 1.72-6.68 | < .001 |
HR indicates hazard ratio; CI, confidence interval; KPS, Karnofsky Performance Score.